(Q57961724)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17295293%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

title

Switching to an aromatase inhibitor provides mortality benefit in early breast carcinoma: pooled analysis of 2 consecutive trials (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17295293%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

0 references

1 reference

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17295293%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

author name string

Francesco Boccardo

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17295293%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Alessandra Rubagotti

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17295293%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Daniela Aldrighetti

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17295293%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Franco Buzzi

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17295293%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Giorgio Cruciani

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17295293%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Antonio Farris

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17295293%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Giorgio Mustacchi

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17295293%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Mauro Porpiglia

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17295293%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Giorgio Schieppati

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17295293%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

language of work or name

English

0 references

publication date

1 March 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17295293%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17295293%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

volume

109

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17295293%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17295293%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

page(s)

1060-1067

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17295293%20AND%20SRC:MED&resulttype=core&format=json

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples

25 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22513

Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22513

7 January 2021

National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22513

7 January 2021

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22513

7 January 2021

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety upda

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22513

7 January 2021

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22513

7 January 2021

Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22513

7 January 2021

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22513

7 January 2021

Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22513

7 January 2021

Quality of health care delivered to adults in the United States

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22513

7 January 2021

Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: results of an Italian cooperative study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22513

7 January 2021

Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22513

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22513

7 January 2021

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22513

7 January 2021

Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22513

7 January 2021

Tamoxifen-treated breast carcinoma patients and the risk of acute myocardial infarction and newly-diagnosed angina

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22513

7 January 2021

Serum cholesterol reduction with tamoxifen

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22513

7 January 2021

Long term effects of tamoxifen on blood lipid values in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22513

7 January 2021

Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22513

7 January 2021

American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22513

7 January 2021

Identifiers

DOI

10.1002/CNCR.22513

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17295293%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

1 reference